Guficap 50mg Injection contains Caspofungin, an echinocandin antifungal agent used for the treatment of invasive fungal infections. It is indicated primarily for invasive candidiasis, including candidemia, and esophageal candidiasis, as well as for invasive aspergillosis in patients who are refractory to or intolerant of other antifungal therapies. Caspofungin acts by inhibiting the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall, leading to cell lysis and death. Administered intravenously, Guficap 50mg Injection is typically given once daily, with dosage adjustments based on the severity of infection, patient weight, and hepatic function. It is generally well-tolerated, with common adverse effects including mild infusion-related reactions, elevated liver enzymes, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment and those receiving concomitant hepatotoxic drugs. Monitoring of liver function tests during therapy is recommended. Guficap should be used under strict medical supervision, with appropriate diagnostic evaluation to confirm fungal infection. Its use contributes significantly to the management of life-threatening fungal infections, particularly in immunocompromised patients, ensuring effective antifungal coverage with a favorable safety profile.